DEFA14A: STAAR Surgical Amends Alcon Merger, Initiates Go-Shop

STAAR Surgical Company has amended its merger agreement with Alcon, introducing a 30-day go-shop period and eliminating termination fees for superior offers from qualified bidders.

Summary

• STAAR Surgical Company (STAA) entered into Amendment No. 1 to its Agreement and Plan of Merger with Alcon Research, LLC (Alcon) and Rascasse Merger Sub, Inc. on November 7, 2025.
• The amendment establishes a 30-day 'go-shop' period from November 7, 2025, until December 6, 2025, allowing STAAR to actively solicit and negotiate alternative acquisition proposals.
• During the go-shop period, STAAR is not required to notify Alcon of any proposals received.
• If STAAR terminates the agreement to accept a superior offer from a 'Qualified Bidder' (a bidder identified during the go-shop period), no termination fee will be payable to Alcon.
• Alcon has waived its right to match any superior offer and is not required to negotiate with STAAR if a superior offer is received.
• The special meeting of STAAR stockholders to vote on the merger proposal has been postponed from December 3, 2025, to December 19, 2025, at 8:30 a.m. Pacific Time.
• The record date for the special meeting remains October 24, 2025.
• Alcon has committed to engage with STAAR stockholders and proxy advisory firms to discuss the merger proposal.

Sentiment

Score: 8

Explanation: The sentiment is positive for STAAR shareholders due to the go-shop period, Alcon's waiver of matching rights, and the $0 termination fee for a superior offer, all of which increase the likelihood of maximizing shareholder value. The only negative is the delay in the merger timeline, but this is outweighed by the potential for a better outcome.

Positives

• The introduction of a 30-day 'go-shop' period allows STAAR to proactively seek higher bids, potentially maximizing shareholder value.
• Alcon has waived its matching rights, meaning STAAR can accept a superior offer without Alcon having the opportunity to counter.
• No termination fee ($0) is payable to Alcon if STAAR accepts a superior offer from a 'Qualified Bidder' identified during the go-shop period, significantly reducing the cost of pursuing a better deal.
• Alcon has waived information rights during the go-shop period, fostering a more open and competitive bidding process.
• Alcon's commitment to engage with STAAR stockholders and proxy advisory firms indicates a willingness to address shareholder concerns and potentially improve the current offer or secure support.

Negatives

• The postponement of the special meeting introduces further delay and uncertainty regarding the merger's completion.
• The go-shop period, while beneficial, does not guarantee a superior offer will materialize, potentially leading to continued market speculation.

Risks

• The occurrence of any event, change, or other circumstances that could lead to the termination of the Alcon merger agreement or cause the proposed transaction to be delayed or fail.
• Failure to obtain approval of the proposed transaction from STAAR's stockholders.
• Failure to obtain required regulatory approvals or satisfy other closing conditions within expected timeframes or at all.
• Disruption of management's attention from ongoing business operations due to the proposed transaction.
• The effect of the announcement of the proposed transaction on STAAR's ability to retain and hire key personnel and maintain relationships with customers, suppliers, and others.
• STAAR's ability to meet expectations regarding the timing and completion of the transaction.
• The possibility that no alternative proposals will be received during the go-shop period, or that any such alternative proposals are not determined by the STAAR board to be superior to the Alcon merger.
• The outcome of any legal proceedings that may be instituted against STAAR related to the proposed transaction.
• The possibility that STAAR's stock price may decline significantly if the proposed transaction is not consummated.

Future Outlook

The company anticipates that the newly introduced go-shop period will either lead to a superior acquisition proposal or validate the merits of the existing merger with Alcon. The outcome of this process is expected to maximize stockholder value. The completion of the merger remains subject to stockholder approval, regulatory approvals, and other closing conditions, with potential risks including delays, failure to obtain approvals, and impacts on business operations and stock price.

Management Comments

• "The STAAR Board continues to be committed to maximizing stockholder value."
• "This go-shop has provisions that encourage all potential buyers to come forward to provide their updated perspectives on valuation based on our most recent financial results and business trends."
• "This go-shop process will either produce a superior proposal or it will validate the merits of our proposed merger with Alcon. Either way, STAAR stockholders win."
• "We look forward to continuing our dialogue with our stockholders during this period."
• "In addition, we are pleased that Alcon has committed to begin engaging with STAAR stockholders and proxy advisory firms to understand their perspectives on valuation and other aspects of the Alcon merger proposal."

Industry Context

This amendment reflects a common strategy in M&A, where a target company, after agreeing to a merger, seeks to ensure it has explored all potential higher offers. The ophthalmic surgery market, particularly for vision correction solutions like phakic IOLs, is competitive and innovative. A go-shop period allows STAAR to leverage its position as a global leader in EVO ICLs to attract potentially more lucrative bids from other industry players or private equity firms, especially given its proprietary biocompatible Collamer material and extensive global presence.

Comparison to Industry Standards

• The inclusion of a 'go-shop' provision is a standard practice in merger agreements, particularly when the target company's board seeks to fulfill its fiduciary duties by ensuring the best possible value for shareholders. This is often seen in deals where the initial offer might be perceived as undervalued by some stakeholders.
• The waiver of matching rights by Alcon is less common and significantly strengthens STAAR's position in attracting superior offers, as potential bidders know their offer won't simply be matched by the incumbent acquirer.
• A $0 termination fee for a superior offer from a qualified bidder is highly favorable to STAAR's shareholders, as it removes a significant financial deterrent for alternative bidders and for STAAR's board to accept a better deal. Typical termination fees range from 1-4% of the deal value, making this a notable concession by Alcon.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased acquisition value due to the go-shop period and favorable termination fee terms. Voting on the merger is postponed, extending the period of uncertainty but also the opportunity for a better outcome.
• Management and Employees: Risk of disruption to ongoing business operations and challenges in retaining key personnel due to the prolonged merger process and uncertainty.
• Customers and Suppliers: Potential for disruption in relationships due to the ongoing merger process and uncertainty about future ownership.

Next Steps

• STAAR Surgical will actively solicit alternative acquisition proposals during the go-shop period until December 6, 2025.
• STAAR and its financial advisor will contact third parties to invite interest in an alternative transaction.
• Alcon will engage with STAAR stockholders and proxy advisory firms to understand their perspectives on valuation and the merger proposal.
• The special meeting of STAAR stockholders will be held on December 19, 2025, to vote on the Alcon merger proposal.
• STAAR will provide a new notice of the Special Meeting to stockholders in advance of December 19, 2025.

Key Dates

Recommendation

The initiation of a go-shop period, coupled with Alcon's waiver of matching rights and a $0 termination fee for a superior offer, creates a significant opportunity for STAAR shareholders to realize a higher acquisition price. While the current Alcon offer is on the table, the go-shop period introduces the potential for a 'better' outcome. Therefore, a 'hold' recommendation is appropriate to allow shareholders to benefit from any potential superior offers that may emerge during this period, rather than selling at the current Alcon offer price or buying into the uncertainty. The stock price is likely to trade close to the Alcon offer price, with some premium for the go-shop optionality, or a discount if the market perceives a low probability of a superior offer.

Keywords

STAAR Surgical, Alcon, Merger Agreement, Go-Shop Period, Acquisition Proposal, Superior Offer, Termination Fee, Proxy Statement, Stockholder Meeting, Ophthalmic Surgery, Implantable Collamer Lenses, EVO ICL, Vision Correction